Abstract
Stroke is a devastating disease with few therapeutic options. Despite our growing understanding of the critical mechanistic events in post-stroke brain injury, the clinical translation of these findings has been less effective. A monumental hurdle to the field has been the inability of many systemically applied therapies to efficiently cross the blood brain barrier (BBB) and enter brain cells. Over the last two decades, however, significant technological achievements have overcome this obstacle to facilitate central nervous system (CNS) drug delivery. Noninvasive drug carriers, especially cell penetrating peptide (CPP) show great potential to deliver neurotherapeutics across the BBB for the treatment of ischemic brain injury. This review begins with a brief introduction to the BBB in relation to drug delivery and then provides an overview of the development of drug carriers for neurotherapeutics, with a focus on CPP-mediated transduction. We discuss recent advances and limitations in this field, as well as mechanisms underlying CPP-mediated brain targeting. We also summarize the application of CPPs in stroke research. Continuing modifications and improvements of CPPs are expected to enhance both their feasibility in clinical stroke management and their specificity towards particular cell types.
Keywords: Cell penetrating peptide, TAT protein transduction domains, blood brain barrier, stroke, neuroprotection, brain cells, central nervous system (CNS), drug delivery, neurotherapeutics, ischemic brain injury.
Current Pharmaceutical Design
Title:Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
Volume: 18 Issue: 25
Author(s): Xiaoming Hu, Meijuan Zhang, Rehana K Leak, Yu Gan, Peiying Li, Yanqin Gao and Jun Chen
Affiliation:
Keywords: Cell penetrating peptide, TAT protein transduction domains, blood brain barrier, stroke, neuroprotection, brain cells, central nervous system (CNS), drug delivery, neurotherapeutics, ischemic brain injury.
Abstract: Stroke is a devastating disease with few therapeutic options. Despite our growing understanding of the critical mechanistic events in post-stroke brain injury, the clinical translation of these findings has been less effective. A monumental hurdle to the field has been the inability of many systemically applied therapies to efficiently cross the blood brain barrier (BBB) and enter brain cells. Over the last two decades, however, significant technological achievements have overcome this obstacle to facilitate central nervous system (CNS) drug delivery. Noninvasive drug carriers, especially cell penetrating peptide (CPP) show great potential to deliver neurotherapeutics across the BBB for the treatment of ischemic brain injury. This review begins with a brief introduction to the BBB in relation to drug delivery and then provides an overview of the development of drug carriers for neurotherapeutics, with a focus on CPP-mediated transduction. We discuss recent advances and limitations in this field, as well as mechanisms underlying CPP-mediated brain targeting. We also summarize the application of CPPs in stroke research. Continuing modifications and improvements of CPPs are expected to enhance both their feasibility in clinical stroke management and their specificity towards particular cell types.
Export Options
About this article
Cite this article as:
Hu Xiaoming, Zhang Meijuan, K Leak Rehana, Gan Yu, Li Peiying, Gao Yanqin and Chen Jun, Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke, Current Pharmaceutical Design 2012; 18 (25) . https://dx.doi.org/10.2174/138161212802002715
DOI https://dx.doi.org/10.2174/138161212802002715 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of STAT 3 in Tissue Fibrosis
Current Chemical Biology Biotechnological Production of Taxol and Related Taxoids: Current State and Prospects
Anti-Cancer Agents in Medicinal Chemistry The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design CRH Receptor Signalling: Potential Roles in Pathophysiology
Current Molecular Pharmacology Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems Therapeutic Implications for Immunophilin Ligands in the Treatment of Neurodegenerative Diseases
Current Drug Targets - CNS & Neurological Disorders Brain Proton Magnetic Resonance Spectroscopy: A Review of Main Metabolites and its Clinical Applications in Gliomas
Current Molecular Imaging (Discontinued) Anti-inflammatory, Antioxidant, Lung and Liver Protective Activity of <i>Galaxaura oblongata</i> as Antagonistic Efficacy against LPS using Hematological Parameters and Immunohistochemistry as Biomarkers
Cardiovascular & Hematological Agents in Medicinal Chemistry Diagnosis and Management of Hypertensive Emergencies Complicating Pregnancy
Current Women`s Health Reviews Preclinical Models of Graves’ Disease and Associated Secondary Complications
Current Pharmaceutical Design New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Molecular Mechanisms Underlying Specificity of Excitotoxic Signaling in Neurons
Current Molecular Medicine Possible Usefulness of Growth Hormone/Insulin-like Growth Factor-I Axis in Alzheimer’s Disease Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Application of MicroPET in Basic Epilepsy Research
Current Medical Imaging High Blood Pressure and the Risk of Stroke
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Current Bioactive Compounds The Glioblastoma Problem: Targeting by Combined Medicinal Chemistry Approaches
Current Medicinal Chemistry Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology